Insights from 2023 ASH Annual Meeting
Avatar

ASH 2023 Insights: "Impact of Dex Dose Strength on Outcomes in NDMM"

By Insights from 2023 ASH Annual Meeting FEATURING Rahul Banerjee
By Insights from 2023 ASH Annual Meeting FEATURING Rahul Banerjee
217 views
December 29, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Related Content

AUTOPLAY
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
12:33
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Minimizing Uncertainty in Multiple Myelom…

Feat. K. Patel
23:09
5th SOHO Italy Annual Conference

SOHO Italy 2023: Is Anti-CD38-Based Induction Therapy for Every Pati…

Feat. P. Richardson
06:11
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "An Outpatient Model for Teclistamab Step-U…

Feat. A. Varshavsky-Yanovsky
41:52
MyCancerHaven

How I Approach Frontline Treatment for Patients With MM

Feat. R. Vij, S. Goyal
25:36
MyCancerHaven

Experts Discuss the Bispecific Antibody Talquetamab in Patients With…

Feat. R. Vij, G. Kaur
31:27
MyCancerHaven

Experts Discuss the Initial Treatment and Monitoring in Multiple Mye…

Feat. R. Vij, A. Nooka
08:48
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Isa-KRd in High-Risk NDMM - Planned Interim…

Feat. L. Leypoldt
10:09
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Next Questions for MM in the Coming 5-10 Years

Feat. T. Martin
30:18
UChicago Medicine

Practice-Changing and Promising New Treatments in Myeloma

Feat. B. Derman
35:24
Louisville Hematology Highlights

Is a Bigger Induction "Hammer" Necessarily Better in Today…

Feat. W. Tse
45:43
MedNews Week

Multiple Myeloma in 2022: Developments, Directions, and Disparities

Feat. J. Mikhael
15:34
MyCancerHaven

Experts Discuss the Use of Monoclonal Antibodies in MM

Feat. R. Vij, S. Goldsmith
14:20
MyCancerHaven

Overview of Proteasome Inhibitors in MM: Bortezomib, Carfilzomib &am…

Feat. R. Vij, S. Ailawadhi
09:57
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "KRd vs. Elotuzumab + KRd in Transplant-El…

Feat. S. Knop
44:44
University of Colorado Division of Hematology

Drug-Resistant Subpopulations in Patients With Multiple Myeloma

Feat. D. Sherbenou
11:54
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Manage Transplant-Eligible Frontline Multiple…

Feat. V. Montefusco
15:39
5th SOHO Italy Annual Conference

SOHO Italy 2023: MRD by NGS in MM

Feat. K. Ramasamy
14:51
Larry Anderson

Multiple Myeloma: Frontline Therapy Updates

08:09
Krina Patel

What Constitutes a Patient That Is Newly Diagnosed With MM as Eligib…